Seres Therapeutics (MCRB) Long-Term Debt Issuances (2014 - 2024)

Seres Therapeutics has reported Long-Term Debt Issuances for 5 years, with the latest figure at $127.9 million in Q3 2024.

• Quarterly Long-Term Debt Issuances changed N/A year-over-year to $127.9 million in Q3 2024, while the trailing twelve-month figure through Dec 2025 was $178.4 million (changed 0.0% YoY) and the FY2024 annual result came in at $127.9 million, up 23.73% from the prior year.
• Long-Term Debt Issuances rose to $127.9 million in Q3 2024 per MCRB's latest filing, from $50.5 million in the prior quarter.
• Over five years, Long-Term Debt Issuances peaked at $127.9 million in Q3 2024 and troughed at -$25.7 million in Q4 2022.
• A 3-year average of $46.6 million and a median of $50.5 million in 2023 frame the typical range for Long-Term Debt Issuances.
• The widest YoY moves for Long-Term Debt Issuances: up 296.58% in 2023, down 296.58% in 2023.
• Over 3 years, Long-Term Debt Issuances stood at -$25.7 million in 2022, then jumped by 296.58% to $50.5 million in 2023, then jumped by 153.19% to $127.9 million in 2024.
• According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $127.9 million, $50.5 million, and $52.9 million for Q3 2024, Q4 2023, and Q2 2023 respectively.